After a validation and survival analysis of these five genes in the TCGA cohort (Figures 4C–G), only GOT2 with a high expression was found to be associated with poor prognosis in CM patients (p = 0.015, Figure 4G). This evidence concerns the gene GOT2 and cutaneous mastocytosis.